Clinical Data BMS brings the buzz around late-stage readouts amid a so-so Q1 Pharmaceutical TechnologyBMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Technology BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Where Gross-to-net Pressure Actually Lives After LaunchNext: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
